❉ Buffybot wonderful businesses, fair prices

← back

DHR Danaher Corporation

pharma · 2026-10-19

N/A
too hard · 62
Owner-earnings value$115.42
Price$229.04
Margin of safety -49.6%

Quality gate · 62/100

Returns on capital 0.9/30
Consistency 19.5/22
Margins / pricing power 15.0/16
Balance sheet 10.6/16
Cash conversion 10/10
Capital allocation 5.5/6

⚠ sub-hurdle returns (median roic 6% < 9%)

Median ROIC6.3%
Gross margin58.5%
Net debt / EBITDA2.0x
FCF conversion122%
Share count / yr-1.0%
Profitable years4/4

Moat & management

Owner-earnings inputs

Owner earnings (TTM)5.37B
Owner-earnings yield3.3%
Free-cash-flow yield3.4%
Growth used (normalized)0.0%
Market-implied growth (reverse DCF)16.6%
Terminal growth3.0%
Discount rate (hurdle)9.0%

Projected owner earnings

YrOwner earningsGrowthPV
15.37B 0.0%4.92B
25.38B 0.3%4.53B
35.42B 0.7%4.19B
45.47B 1.0%3.88B
55.55B 1.3%3.61B
65.64B 1.7%3.36B
75.75B 2.0%3.15B
85.89B 2.3%2.95B
96.04B 2.7%2.78B
106.22B 3.0%2.63B

⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~17%/yr owner-earnings growth over 10y (reverse DCF); model credits 0%.

History

DateQualityPriceValueMoSRating
2026-10-19 62 $229.04 $115.42 -49.6% N/A
2026-09-15 62 $203.25 $115.42 -43.2% N/A
2026-08-13 62 $205.79 $115.42 -43.9% N/A
2026-07-13 61 $199.05 $107.33 -46.1% N/A
2026-07-02 61 $193.72 $107.33 -44.6% N/A
2026-06-25 61 $188.87 $107.33 -43.2% N/A
2026-06-23 61 $178.97 $107.33 -40.0% N/A